Cover Image
市場調查報告書

IVD (體外診斷) 市場:產品,技術,用途,各終端用戶 - 全球機會分析及產業預測

IVD Market by Product Type (Reagents, Instruments and Software & Services), by Technique, by Application, by End Users - Global Opportunity Analysis and Industry Forecast, 2017-2023

出版商 Allied Market Research 商品編碼 563263
出版日期 內容資訊 英文 240 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
IVD (體外診斷) 市場:產品,技術,用途,各終端用戶 - 全球機會分析及產業預測 IVD Market by Product Type (Reagents, Instruments and Software & Services), by Technique, by Application, by End Users - Global Opportunity Analysis and Industry Forecast, 2017-2023
出版日期: 2017年09月01日 內容資訊: 英文 240 Pages
簡介

本報告提供全球IVD (體外診斷) 市場相關調查,彙整市場趨勢與各產品,各技術,各用途,各終端用戶,各地區趨勢,及打入市場的主要企業簡介等資料。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 主要調查結果
  • 波特五力分析
  • 市場佔有率分析
  • 市場趨勢
    • 促進要素
    • 阻礙要素
    • 機會

第4章 產品不同設備市場

  • 概要
  • 試劑
  • 設備
  • 軟體·服務

第5章 各技術市場

  • 概要
  • 免疫診斷
  • 血液檢驗
  • 分子診斷
  • 組織診斷
  • 臨床化學
  • 其他

第6章 各用途市場

  • 感染疾病
  • 癌症
  • 心臟病
  • 免疫系不全
  • 神經疾病
  • 腸胃疾病
  • 其他

第7章 各終端用戶市場

  • 獨立型實驗室
  • 醫院
  • 學術·醫學學校
  • 就地檢驗
  • 其他

第8章 各地區市場

  • 北美
  • 歐洲
  • 亞太地區
  • 南美

第9章 企業簡介

目錄
Product Code: LI 17336

In vitro diagnostics (IVD) is the technique in which medical devices and reagents are used to examine specimens such as blood, urine, stool, tissues, and other body fluids, which are derived from the human body to detect diseases, conditions, and infections. These tests can be performed in stand-alone laboratories, and hospitals- Some of the significant technologies incorporated in vitro diagnostics include polymerase chain reaction (PCR), microarray techniques, sequencing technology, and mass spectrometry, which are used for test sample preparation. Incessant innovations in IVD product design and technology have encouraged doctors and researchers to shift their focus from traditional diagnostic methods to personalized medicines.

There is a growth in need of IVD testing due to increase in incidences of chronic and infectious diseases and rise in geriatric population prone to immunological disorders. Moreover, increased application of personalized medicines and widespread knowledge of rare diseases boost the growth of the IVD market. In addition, increase in incidences of colorectal cancer, neurological disorders, and gynecological diseases boost the adoption of IVD devices and reagents. On the contrary, stringent government regulations and unfavorable reimbursement policies limit the growth of the market. The global IVD market is accounted for $61,103 million in 2016, and is estimated to reach at $84,647 million by 2023, growing at a CAGR of 4.6% from 2017-2023.

The market is segmented on the basis of product type, techniques, application, end-user, and geography. By product type, the market is categorized into reagents, instruments, and software & services. On the basis of techniques, it is categorized into immunodiagnostics, blood testing, molecular diagnostics, tissue diagnostics, clinical chemistry, and other IVD techniques. By application, the market is classified into infectious diseases, cancer, cardiac diseases, immune system disorders, nephrological diseases, gastrointestinal diseases, and other indications. Based on end-user, it is divided into hospitals, academic and medical schools, point of care testing, and others. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the global IVD market, with current trends and future estimations to elucidate the investment pockets.
  • Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
  • The report provides a quantitative analysis to help the stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis of different segments facilitates to understand various products of the market.
  • Key players are profiled and their strategies are analyzed thoroughly, which predict the competitive outlook of the market.

KEY MARKET SEGMENTS

By Product Type

  • Reagents
  • Instruments
  • Software and Services

By Techniques

  • Immunodiagnostics
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Chemiluminescence Immunoassays (CLIAS)
  • Fluorescence Immunoassays (FIAS)
  • Colorimetric Immunoassays (CIS)
  • Rapid Tests
  • Enzyme-Linked Immunospot Assays (ELISPOT)
  • Radioimmunoassay
  • Western Blot
  • Blood Testing
  • Molecular Diagnostics
  • Polymerase Chain Reaction (PCR)
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
  • Hybridization
  • DNA Diagnostics
  • Microarrays
  • Others
  • Tissue Diagnostics
  • Clinical Chemistry
  • Basic Metabolic Panel
  • Liver Panel
  • Lipid Profile
  • Thyroid Function Panel
  • Renal Profile
  • Electrolyte Panel
  • Specialty Chemicals
  • Other IVD Techniques

By Application

  • Infectious Diseases
  • Cancer
  • Cardiac Diseases
  • Immune System Disorders
  • Nephrological Diseases
  • Gastrointestinal Diseases
  • Other Indications

By End Users

  • Standalone Laboratory
  • Hospitals
  • Academic and Medical Schools
  • Point of Care Testing
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Latin America
  • Middle East
  • Africa
  • List of players profiled in the report
  • Thermo Fisher Scientific Inc.
  • Alere Inc.
  • Biomerieux
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Becton Dickinson and Company
  • Bio-Rad Laboratories
  • Bayer AG
  • Sysmex Corporation
  • Johnson & Johnson

Table of Contents

CHAPTER 1 INTRODUCTION

  • 1.1 REPORT DESCRIPTION
  • 1.2 KEY BENEFITS
  • 1.3 KEY MARKET SEGMENTS
  • 1.4 RESEARCH METHODOLOGY
    • 1.4.1 Secondary research
    • 1.4.2 Primary research
    • 1.4.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

  • 2.1 CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

  • 3.1 MARKET DEFINITION AND SCOPE
  • 3.2 KEY FINDINGS
    • 3.2.1 Top investment pockets
    • 3.2.2 Top winning strategies
  • 3.3 PORTERS FIVE FORCES ANALYSIS
    • 3.3.1 Bargaining power of suppliers
    • 3.3.2 Bargaining power of buyers
    • 3.3.3 Threat of new entrants
    • 3.3.4 Threat of substitute
    • 3.3.5 Competitive rivalry
  • 3.4 MARKET SHARE ANALYSIS, 2016
  • 3.5 MARKET DYNAMICS
    • 3.5.1 Drivers
      • 3.5.1.1 Increasing incidence of chronic and infectious diseases
      • 3.5.1.2 Technological advancements in IVD
      • 3.5.1.3 Emergence of minimal invasive technologies
      • 3.5.1.4 Increasing government expenditures on healthcare
      • 3.5.1.5 Increase in popularity of personalized medicine approach
    • 3.5.2 Restraint
      • 3.5.2.1 Unclear reimbursement policies
      • 3.5.2.2 Stringent regulatory policies
    • 3.5.3 Opportunity
      • 3.5.3.1 Potential opportunities for outsourcing
      • 3.5.3.2 Convergence of new technologies

CHAPTER 4 IVD MARKET, BY PRODUCT TYPE

  • 4.1 OVERVIEW
    • 4.1.1 Market size and forecast
  • 4.2 REAGENTS
    • 4.2.1 Key market trends
    • 4.2.2 Key growth factors and opportunities
    • 4.2.3 Market size and forecast
  • 4.3 INSTRUMENTS
    • 4.3.1 Key market trends
    • 4.3.2 Key growth factors and opportunities
    • 4.3.3 Market size and forecast
  • 4.4 SOFTWARE AND SERVICES
    • 4.4.1 Key market trends
    • 4.4.2 Key growth factors and opportunities
    • 4.4.3 Market size and forecast

CHAPTER 5 IVD MARKET, BY TECHNIQUE

  • 5.1 OVERVIEW
    • 5.1.1 Market size and forecast
  • 5.2 IMMUNODIAGNOSTICS
    • 5.2.1 Key market trends
    • 5.2.2 Key growth factors and opportunities
    • 5.2.3 Market size and forecast
    • 5.2.4 Enzyme-linked immunosorbent assay (ELISA)
      • 5.2.4.1 Market size and forecast
      • 5.2.4.2 Chemiluminescence immunoassay (CLIA)
      • 5.2.4.2.1 Market size and forecast
      • 5.2.4.3 Fluorescence immunoassay (FIA)
      • 5.2.4.3.1 Market size and forecast
      • 5.2.4.4 Colorimetric immunoassay (CI)
      • 5.2.4.4.1 Market size and forecast
    • 5.2.5 Rapid tests
      • 5.2.5.1 Market size and forecast
    • 5.2.6 Enzyme-linked immunospot (ELISPOT)
      • 5.2.6.1 Market size and forecast
    • 5.2.7 Radioimmunoassay (RIA)
      • 5.2.7.1 Market size and forecast
    • 5.2.8 Western blot
      • 5.2.8.1 Market size and forecast
  • 5.3 BLOOD TESTING
    • 5.3.1 Key market trends
    • 5.3.2 Key growth factors and opportunities
    • 5.3.3 Market size and forecast
  • 5.4 MOLECULAR DIAGNOSTICS
    • 5.4.1 Key market trends
    • 5.4.2 Key growth factors and opportunities
    • 5.4.3 Market size and forecast
    • 5.4.4 Polymerize chain reaction (PCR)
      • 5.4.4.1 Market size and forecast
    • 5.4.5 Isothermal nucleic acid technology (INAAT)
      • 5.4.5.1 Market size and forecast
    • 5.4.6 Hybridization
      • 5.4.6.1 Market size and forecast
    • 5.4.7 DNA diagnostics
      • 5.4.7.1 Market size and forecast
    • 5.4.8 Microarray
      • 5.4.8.1 Market size and forecast
    • 5.4.9 Others
      • 5.4.9.1 Market size and forecast
  • 5.5 TISSUE DIAGNOSTICS
    • 5.5.1 Key market trends
    • 5.5.2 Key growth factors and opportunities
    • 5.5.3 Market size and forecast
  • 5.6 CLINICAL CHEMISTRY
    • 5.6.1 Key market trends
    • 5.6.2 Key growth factors and opportunities
    • 5.6.3 Market size and forecast
    • 5.6.4 Basic metabolic panel
      • 5.6.4.1 Market size and forecast
    • 5.6.5 Liver panel
      • 5.6.5.1 Market size and forecast
    • 5.6.6 Renal profile
      • 5.6.6.1 Market size and forecast
    • 5.6.7 Lipid profile
      • 5.6.7.1 Market size and forecast
    • 5.6.8 Thyroid function panel
      • 5.6.8.1 Market size and forecast
    • 5.6.9 Electrolyte panel
      • 5.6.9.1 Market size and forecast
    • 5.6.10 Speciality chemicals
      • 5.6.10.1 Market size and forecast
  • 5.7 OTHER IVD TECHNIQUES
    • 5.7.1 Key market trends
    • 5.7.2 Key growth factors and opportunities
    • 5.7.3 Market size and forecast

CHAPTER 6 IVD MARKET, BY APPLICATION

  • 6.1 INFECTIOUS DISEASES
    • 6.1.1 Key market trends
    • 6.1.2 Key growth factors and opportunities
    • 6.1.3 Market size and forecast
  • 6.2 CANCER
    • 6.2.1 Key market trends
    • 6.2.2 Key growth factors and opportunities
    • 6.2.3 Market size and forecast
  • 6.3 CARDIAC DISEASES
    • 6.3.1 Key market trends
    • 6.3.2 Key growth factors and opportunities
    • 6.3.3 Market size and forecast
  • 6.4 IMMUNE SYSTEM DISORDERS
    • 6.4.1 Key market trends
    • 6.4.2 Key growth factors and opportunities
    • 6.4.3 Market size and forecast
  • 6.5 NEPHROLOGICAL DISEASES
    • 6.5.1 Key market trends
    • 6.5.2 Key growth factors and opportunities
    • 6.5.3 Market size and forecast
  • 6.6 GASTROINTESTINAL DISEASES
    • 6.6.1 Key market trends
    • 6.6.2 Key growth factors and opportunities
    • 6.6.3 Market size and forecast
  • 6.7 OTHERS INDICATIONS
    • 6.7.1 Key market trends
    • 6.7.2 Key growth factors and opportunities
    • 6.7.3 Market size and forecast

CHAPTER 7 IVD MARKET BY END USERS

  • 7.1 STANDALONE LABORATORIES
    • 7.1.1 Market size and forecast
  • 7.2 HOSPITALS
    • 7.2.1 Key market trends
    • 7.2.2 Key growth factors and opportunities
    • 7.2.3 Market size and forecast
  • 7.3 ACADEMIC AND MEDICAL SCHOOLS
    • 7.3.1 Key market trends
    • 7.3.2 Key growth factors and opportunities
    • 7.3.3 Market size and forecast
  • 7.4 POINT OF CARE TESTING
    • 7.4.1 Key market trends
    • 7.4.2 Key growth factors and opportunities
    • 7.4.3 Market size and forecast
  • 7.5 OTHERS END-USER
    • 7.5.1 Key market trends
    • 7.5.2 Key growth factors and opportunities
    • 7.5.3 Market size and forecast

CHAPTER 8 IVD MARKET BY GEOGRAPHY

  • 8.1 OVERVIEW
    • 8.1.1 Market size and forecast
  • 8.2 NORTH AMERICA
    • 8.2.1 Key market trends
    • 8.2.2 Key growth factors and opportunities
    • 8.2.3 Market size and forecast
    • 8.2.4 U.S.
      • 8.2.4.1 Market size and forecast
    • 8.2.5 Canada
      • 8.2.5.1 Market size and forecast
    • 8.2.6 Mexico
      • 8.2.6.1 Market size and forecast
  • 8.3 EUROPE
    • 8.3.1 Key market trends
    • 8.3.2 Key growth factors and opportunities
    • 8.3.3 Market size and forecast
    • 8.3.4 Germany
      • 8.3.4.1 Market size and forecast
    • 8.3.5 France
      • 8.3.5.1 Market size and forecast
    • 8.3.6 UK
      • 8.3.6.1 Market size and forecast
    • 8.3.7 SPAIN
      • 8.3.7.1 Market size and forecast
    • 8.3.8 ITALY
      • 8.3.8.1 Market size and forecast
    • 8.3.9 Rest of Europe
      • 8.3.9.1 Market size and forecast
  • 8.4 ASIA-PACIFIC
    • 8.4.1 Key market trends
    • 8.4.2 Key growth factors and opportunities
    • 8.4.3 Market size and forecast
    • 8.4.4 India
      • 8.4.4.1 Market size and forecast
    • 8.4.5 China
      • 8.4.5.1 Market size and forecast
    • 8.4.6 Japan
      • 8.4.6.1 Market size and forecast
    • 8.4.7 Australia
      • 8.4.7.1 Market size and forecast
    • 8.4.8 South Korea
      • 8.4.8.1 Market size and forecast
    • 8.4.9 Rest of Asia-Pacific
      • 8.4.9.1 Market size and forecast
  • 8.5 LAMEA
    • 8.5.1 Key market trends
    • 8.5.2 Key growth factors and opportunities
    • 8.5.3 Market size and forecast
    • 8.5.4 Latin America
      • 8.5.4.1 Market size and forecast
    • 8.5.5 Middle East
      • 8.5.5.1 Market size and forecast
    • 8.5.6 Africa
      • 8.5.6.1 Market size and forecast

CHAPTER 9 COMPANY PROFILES

  • 9.1 THERMO FISHER SCIENTIFIC INC.
    • 9.1.1 Company overview
    • 9.1.2 Business performance
    • 9.1.3 Key strategies and development
  • 9.2 ALERE INC.
    • 9.2.1 Company overview
    • 9.2.2 Business performance
    • 9.2.3 Key strategies and developments
  • 9.3 BIOMERIEUX
    • 9.3.1 Company overview
    • 9.3.2 Business performance
    • 9.3.3 Key strategies and developments
  • 9.4 DANAHER CORPORATION
    • 9.4.1 Company overview
    • 9.4.2 Business performance
    • 9.4.3 Key strategies and development
  • 9.5 F. HOFFMANN-LA ROCHE AG
    • 9.5.1 Company overview
    • 9.5.2 Business performance
    • 9.5.3 Key strategies and developments
  • 9.6 BECTON DICKINSON AND COMPANY
    • 9.6.1 Company overview
    • 9.6.2 Business performance
    • 9.6.3 Key strategies and development
  • 9.7 BIO-RAD LABORATORIES
    • 9.7.1 Company overview
    • 9.7.2 Business performance
    • 9.7.3 Key strategies and developments
  • 9.8 BAYER AG
    • 9.8.1 Company overview
    • 9.8.2 Business performance
    • 9.8.3 Key strategies and development
  • 9.9 SYSMEX CORPORATION
    • 9.9.1 Company overview
    • 9.9.2 Business performance
    • 9.9.3 Key strategies and developments
  • 9.10 JOHNSON & JOHNSON
    • 9.10.1 Company overview
    • 9.10.2 Business performance
    • 9.10.3 Key strategies and development
Back to Top